- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06558825
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women With Trauma-related Conditions
Ontwikkeling en pilottesten van een op de geestelijke gezondheidszorg gebaseerde interventie voor de opname en therapietrouw van PrEP voor vrouwen in behandeling voor traumagerelateerde aandoeningen
The investigators have previously developed an integrated bio-behavioral intervention to promote PrEP uptake and adherence in cisgender women who are undergoing treatment for trauma-related mental health conditions and who are at a higher risk for HIV. The intervention is delivered within the mental health treatment setting and integrates knowledge, behavioral skills, and motivation to engage in and adhere to PrEP care. The purpose of this study is to assess the preliminary efficacy, feasibility, and acceptability of this intervention. The hypothesis is that, compared to standard treatment, the intervention will be feasible, acceptable, and associated with greater PrEP uptake and adherence.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The new integrated intervention will include motivational counseling guided by the Information Motivation-Behavioral Skills Model (IMB) which seeks to influence behavior change via information sharing, increasing motivation for change, and teaching behavioral skills to increase self-efficacy. This novel intervention will be delivered remotely using the emocha Mobile Health smartphone application. We expect that, compared to standard SUD treatment only, the integrated intervention will be associated with higher rates of PrEP uptake and adherence.This study will 1) Collect information on knowledge and attitudes about PrEP use and obtain feedback about the potential design of the integrated behavioral intervention from women undergoing treatment for trauma-related conditions who are at risk for HIV and their providers; 2) Develop an integrated behavioral intervention to promote PrEP uptake and adherence in women undergoing treatment for trauma-related conditions who are at high risk for HIV, and 3) Assess feasibility, acceptability and initial efficacy of the intervention.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77054
- Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Currently undergoing mental health treatment;
- Have a history of trauma;
- HIV negative;
- Sexually active with an opposite sex partner within the past 6 months;
- Not using PrEP for HIV prevention at the time of screening;
- Eligible for PrEP based on having at least one Centers for Disease Control and Prevention (CDC)-defined criteria for PrEP;
- Fluent in English;
- Own or have regular access to a smart phone.
Exclusion Criteria:
- HIV positive;
- Concurrently participating in another HIV prevention program;
- Have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy;
- Have psychological distress that would prohibit them from participating in the study;
- Be unable or unwilling to meet study requirements.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Geïntegreerde interventie om de opname van PrEP te bevorderen
|
Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting. |
|
Actieve vergelijker: Standaard behandelingsconditie
|
Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants who uptake PrEP
Tijdsspanne: 12 weeks post intervention
|
PrEP uptake is defined as obtaining a prescription and taking the first dose. |
12 weeks post intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Haalbaarheid van de interventie zoals beoordeeld aan de hand van het aantal sessies dat door de deelnemers werd bijgewoond
Tijdsspanne: 15 weken na inschrijving
|
15 weken na inschrijving
|
|
|
Number of Participants who adhere to PrEP
Tijdsspanne: 12 weeks post PrEP initiation
|
PrEP adherence is lab confirmed and is defined as having adequate levels of tenofovir (TFV) (>1000ng/ml). |
12 weeks post PrEP initiation
|
|
PrEP adherence as assessed by proportion of videos uploaded
Tijdsspanne: from the time of PrEP initiation to 12 weeks post PrEP initiation
|
In the intervention arm, participants are asked to take a video of themselves taking PrEP. Videos are uploaded through an app, which is offered in the intervention arm only (and not the standard treatment arm). Data will be reported as the number of days a video is uploaded divided by the number of days of the intervention period. |
from the time of PrEP initiation to 12 weeks post PrEP initiation
|
|
PrEP adherence as assessed by proportion of self-reported daily adherence
Tijdsspanne: from the time of PrEP initiation to 12 weeks post PrEP initiation
|
In both arms, participants are sent a questionnaires weekly in which they record the number of days they took PrEP over the past seven days. Data will be reported as the number of days PrEP is taken divided by the number of days of the intervention period. |
from the time of PrEP initiation to 12 weeks post PrEP initiation
|
|
Intervention feasibility as assessed by number of participants enrolled
Tijdsspanne: at the time of enrollment
|
The number enrolled is the number of participants who signed the consent form. |
at the time of enrollment
|
|
Intervention feasibility as assessed by study retention
Tijdsspanne: 15 weeks post enrollment
|
Study retention is assessed by the the number of participants who completed the study. |
15 weeks post enrollment
|
|
Intervention acceptability as assessed by score on a satisfaction questionnaire
Tijdsspanne: 15 weeks post enrollment
|
This is a 15 item questionnaire and each item is scored from 1 (not at all true) to 9 (absolutely true). Total score ranges from 15 to 135, with a higher score indicating greater satisfaction. |
15 weeks post enrollment
|
|
Change in PrEP Anticipated Stigma as assessed by the PrEP Anticipated Stigma Scale
Tijdsspanne: baseline, 15 weeks post enrollment
|
Total score ranges from 8 to 32, with a higher score indicating greater stigma. |
baseline, 15 weeks post enrollment
|
|
Change in perceived HIV risk as assessed by Perceived Risk of HIV Scale
Tijdsspanne: baseline, 15 weeks post enrollment
|
Total score ranges from 10 to 40, with a higher score indicating a greater perceived HIV risk. |
baseline, 15 weeks post enrollment
|
|
Change in PrEP knowledge as assessed by PrEP Knowledge Questionnaire
Tijdsspanne: baseline, 15 weeks post enrollment
|
Total score ranges from 0 to 6, with a higher score indicating a greater knowledge about PrEP. |
baseline, 15 weeks post enrollment
|
|
Change in PrEP attitudes as assessed by PrEP Attitudes Measure
Tijdsspanne: baseline, 15 weeks post enrollment
|
Total score ranges from 5.2 to 26, with a higher score indicating a better attitude toward PrEP. |
baseline, 15 weeks post enrollment
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Angela Heads, PhD, The University of Texas Health Science Center, Houston
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HSC-MS-21-0544
- 1R34DA055496-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .